CNTB•benzinga•
Connect Biopharma Reports H1 2022 Cash, Cash Equivalents, And Short-term And Long-term Investments Were $212.9M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 13, 2022 by benzinga